nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—acquired immunodeficiency syndrome	0.279	1	CbGaD
Canagliflozin—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.0683	0.125	CbGbCtD
Canagliflozin—ABCC2—Indinavir—acquired immunodeficiency syndrome	0.0525	0.0963	CbGbCtD
Canagliflozin—ABCC2—Saquinavir—acquired immunodeficiency syndrome	0.0461	0.0845	CbGbCtD
Canagliflozin—ABCC2—Ritonavir—acquired immunodeficiency syndrome	0.0461	0.0845	CbGbCtD
Canagliflozin—ABCC2—Lamivudine—acquired immunodeficiency syndrome	0.0342	0.0627	CbGbCtD
Canagliflozin—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0288	0.0527	CbGbCtD
Canagliflozin—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0276	0.0505	CbGbCtD
Canagliflozin—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0219	0.0402	CbGbCtD
Canagliflozin—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0198	0.0364	CbGbCtD
Canagliflozin—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0171	0.0314	CbGbCtD
Canagliflozin—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0166	0.0305	CbGbCtD
Canagliflozin—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.015	0.0275	CbGbCtD
Canagliflozin—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.015	0.0275	CbGbCtD
Canagliflozin—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0144	0.0264	CbGbCtD
Canagliflozin—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.014	0.0256	CbGbCtD
Canagliflozin—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0131	0.0241	CbGbCtD
Canagliflozin—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0131	0.0241	CbGbCtD
Canagliflozin—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0119	0.0218	CbGbCtD
Canagliflozin—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0119	0.0218	CbGbCtD
Canagliflozin—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0112	0.0204	CbGbCtD
Canagliflozin—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0103	0.0188	CbGbCtD
Canagliflozin—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00996	0.0183	CbGbCtD
Canagliflozin—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00901	0.0165	CbGbCtD
Canagliflozin—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00901	0.0165	CbGbCtD
Canagliflozin—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00864	0.0158	CbGbCtD
Canagliflozin—SLC5A2—blood plasma—acquired immunodeficiency syndrome	0.00774	0.202	CbGeAlD
Canagliflozin—ORM1—saliva—acquired immunodeficiency syndrome	0.00446	0.116	CbGeAlD
Canagliflozin—SLC5A2—blood—acquired immunodeficiency syndrome	0.00284	0.0739	CbGeAlD
Canagliflozin—SLC5A2—vagina—acquired immunodeficiency syndrome	0.00263	0.0685	CbGeAlD
Canagliflozin—SLC5A1—digestive system—acquired immunodeficiency syndrome	0.00226	0.0588	CbGeAlD
Canagliflozin—SLC5A1—vagina—acquired immunodeficiency syndrome	0.00199	0.0519	CbGeAlD
Canagliflozin—SLC5A1—lung—acquired immunodeficiency syndrome	0.00188	0.0491	CbGeAlD
Canagliflozin—UGT2B4—lung—acquired immunodeficiency syndrome	0.00174	0.0453	CbGeAlD
Canagliflozin—UGT1A9—digestive system—acquired immunodeficiency syndrome	0.00142	0.037	CbGeAlD
Canagliflozin—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000811	0.0211	CbGeAlD
Canagliflozin—ORM1—blood—acquired immunodeficiency syndrome	0.000712	0.0186	CbGeAlD
Canagliflozin—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000689	0.018	CbGeAlD
Canagliflozin—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000686	0.0179	CbGeAlD
Canagliflozin—ORM1—lung—acquired immunodeficiency syndrome	0.000624	0.0163	CbGeAlD
Canagliflozin—ABCC2—digestive system—acquired immunodeficiency syndrome	0.000614	0.016	CbGeAlD
Canagliflozin—ABCC2—blood—acquired immunodeficiency syndrome	0.000585	0.0152	CbGeAlD
Canagliflozin—ORM1—nervous system—acquired immunodeficiency syndrome	0.000578	0.0151	CbGeAlD
Canagliflozin—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000574	0.015	CbGeAlD
Canagliflozin—ORM1—central nervous system—acquired immunodeficiency syndrome	0.000556	0.0145	CbGeAlD
Canagliflozin—ORM1—lymph node—acquired immunodeficiency syndrome	0.000427	0.0111	CbGeAlD
Canagliflozin—ALB—brain—acquired immunodeficiency syndrome	0.000387	0.0101	CbGeAlD
Canagliflozin—ALB—lymph node—acquired immunodeficiency syndrome	0.000374	0.00976	CbGeAlD
Canagliflozin—ABCC2—lymph node—acquired immunodeficiency syndrome	0.000351	0.00914	CbGeAlD
Canagliflozin—Convulsion—Abacavir—acquired immunodeficiency syndrome	0.000342	0.00251	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Saquinavir—acquired immunodeficiency syndrome	0.000342	0.00251	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.00034	0.00249	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.000339	0.00249	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Amprenavir—acquired immunodeficiency syndrome	0.000338	0.00248	CcSEcCtD
Canagliflozin—Urinary tract infection—Ritonavir—acquired immunodeficiency syndrome	0.000337	0.00247	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.000334	0.00245	CcSEcCtD
Canagliflozin—Dry mouth—Stavudine—acquired immunodeficiency syndrome	0.000334	0.00245	CcSEcCtD
Canagliflozin—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.000332	0.00244	CcSEcCtD
Canagliflozin—Pollakiuria—Lamivudine—acquired immunodeficiency syndrome	0.00033	0.00242	CcSEcCtD
Canagliflozin—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.000329	0.00241	CcSEcCtD
Canagliflozin—Abdominal pain—Amprenavir—acquired immunodeficiency syndrome	0.000327	0.0024	CcSEcCtD
Canagliflozin—Urinary tract infection—Saquinavir—acquired immunodeficiency syndrome	0.000324	0.00238	CcSEcCtD
Canagliflozin—Malnutrition—Indinavir—acquired immunodeficiency syndrome	0.000324	0.00238	CcSEcCtD
Canagliflozin—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.000321	0.00235	CcSEcCtD
Canagliflozin—Infection—Abacavir—acquired immunodeficiency syndrome	0.00032	0.00235	CcSEcCtD
Canagliflozin—Angiopathy—Efavirenz—acquired immunodeficiency syndrome	0.000319	0.00234	CcSEcCtD
Canagliflozin—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000319	0.00234	CcSEcCtD
Canagliflozin—Angioedema—Zidovudine—acquired immunodeficiency syndrome	0.000318	0.00234	CcSEcCtD
Canagliflozin—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.000318	0.00233	CcSEcCtD
Canagliflozin—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.000316	0.00232	CcSEcCtD
Canagliflozin—ABCB1—retina—acquired immunodeficiency syndrome	0.000314	0.0082	CbGeAlD
Canagliflozin—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.000313	0.0023	CcSEcCtD
Canagliflozin—Syncope—Zidovudine—acquired immunodeficiency syndrome	0.000312	0.00229	CcSEcCtD
Canagliflozin—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000312	0.00813	CbGeAlD
Canagliflozin—Gastrointestinal pain—Didanosine—acquired immunodeficiency syndrome	0.000308	0.00226	CcSEcCtD
Canagliflozin—Urinary tract disorder—Ritonavir—acquired immunodeficiency syndrome	0.000307	0.00225	CcSEcCtD
Canagliflozin—Loss of consciousness—Zidovudine—acquired immunodeficiency syndrome	0.000306	0.00225	CcSEcCtD
Canagliflozin—Malnutrition—Efavirenz—acquired immunodeficiency syndrome	0.000306	0.00225	CcSEcCtD
Canagliflozin—Erythema—Efavirenz—acquired immunodeficiency syndrome	0.000306	0.00225	CcSEcCtD
Canagliflozin—Urethral disorder—Ritonavir—acquired immunodeficiency syndrome	0.000305	0.00224	CcSEcCtD
Canagliflozin—Convulsion—Zidovudine—acquired immunodeficiency syndrome	0.000302	0.00221	CcSEcCtD
Canagliflozin—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.000301	0.00221	CcSEcCtD
Canagliflozin—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.000298	0.00219	CcSEcCtD
Canagliflozin—CYP3A4—blood—acquired immunodeficiency syndrome	0.000297	0.00775	CbGeAlD
Canagliflozin—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.000297	0.00218	CcSEcCtD
Canagliflozin—Angioedema—Indinavir—acquired immunodeficiency syndrome	0.000296	0.00217	CcSEcCtD
Canagliflozin—Urinary tract disorder—Saquinavir—acquired immunodeficiency syndrome	0.000296	0.00217	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.000295	0.00216	CcSEcCtD
Canagliflozin—Urethral disorder—Saquinavir—acquired immunodeficiency syndrome	0.000294	0.00215	CcSEcCtD
Canagliflozin—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.000293	0.00215	CcSEcCtD
Canagliflozin—Erythema—Delavirdine—acquired immunodeficiency syndrome	0.000293	0.00215	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000293	0.00215	CcSEcCtD
Canagliflozin—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.000292	0.00215	CcSEcCtD
Canagliflozin—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.000292	0.00214	CcSEcCtD
Canagliflozin—Syncope—Indinavir—acquired immunodeficiency syndrome	0.000291	0.00213	CcSEcCtD
Canagliflozin—Loss of consciousness—Indinavir—acquired immunodeficiency syndrome	0.000285	0.00209	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000283	0.00208	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000282	0.00207	CcSEcCtD
Canagliflozin—Angiopathy—Ritonavir—acquired immunodeficiency syndrome	0.000282	0.00207	CcSEcCtD
Canagliflozin—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000282	0.00207	CcSEcCtD
Canagliflozin—Constipation—Stavudine—acquired immunodeficiency syndrome	0.00028	0.00205	CcSEcCtD
Canagliflozin—Shock—Zidovudine—acquired immunodeficiency syndrome	0.00028	0.00205	CcSEcCtD
Canagliflozin—Angioedema—Efavirenz—acquired immunodeficiency syndrome	0.00028	0.00205	CcSEcCtD
Canagliflozin—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000279	0.00205	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000278	0.00204	CcSEcCtD
Canagliflozin—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000278	0.00204	CcSEcCtD
Canagliflozin—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.000278	0.00204	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.000277	0.00203	CcSEcCtD
Canagliflozin—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000276	0.00203	CcSEcCtD
Canagliflozin—Syncope—Efavirenz—acquired immunodeficiency syndrome	0.000275	0.00201	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000274	0.00201	CcSEcCtD
Canagliflozin—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.00199	CcSEcCtD
Canagliflozin—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000271	0.00199	CcSEcCtD
Canagliflozin—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00027	0.00198	CcSEcCtD
Canagliflozin—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.00027	0.00198	CcSEcCtD
Canagliflozin—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000269	0.00197	CcSEcCtD
Canagliflozin—Loss of consciousness—Efavirenz—acquired immunodeficiency syndrome	0.000269	0.00197	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000268	0.00197	CcSEcCtD
Canagliflozin—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000268	0.00197	CcSEcCtD
Canagliflozin—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.000268	0.00196	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000268	0.00196	CcSEcCtD
Canagliflozin—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000267	0.00196	CcSEcCtD
Canagliflozin—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.000265	0.00195	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000264	0.00193	CcSEcCtD
Canagliflozin—Syncope—Delavirdine—acquired immunodeficiency syndrome	0.000263	0.00193	CcSEcCtD
Canagliflozin—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.000261	0.00191	CcSEcCtD
Canagliflozin—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000261	0.00191	CcSEcCtD
Canagliflozin—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000261	0.00191	CcSEcCtD
Canagliflozin—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000261	0.00191	CcSEcCtD
Canagliflozin—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00026	0.00191	CcSEcCtD
Canagliflozin—Shock—Indinavir—acquired immunodeficiency syndrome	0.00026	0.00191	CcSEcCtD
Canagliflozin—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.00026	0.00191	CcSEcCtD
Canagliflozin—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000259	0.0019	CcSEcCtD
Canagliflozin—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000259	0.0019	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000259	0.0019	CcSEcCtD
Canagliflozin—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000259	0.0019	CcSEcCtD
Canagliflozin—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.000257	0.00189	CcSEcCtD
Canagliflozin—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000257	0.00188	CcSEcCtD
Canagliflozin—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000256	0.00188	CcSEcCtD
Canagliflozin—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000255	0.00187	CcSEcCtD
Canagliflozin—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000255	0.00187	CcSEcCtD
Canagliflozin—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00025	0.00183	CcSEcCtD
Canagliflozin—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.000249	0.00182	CcSEcCtD
Canagliflozin—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000249	0.00182	CcSEcCtD
Canagliflozin—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000246	0.0018	CcSEcCtD
Canagliflozin—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000246	0.0018	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000245	0.0018	CcSEcCtD
Canagliflozin—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000245	0.0018	CcSEcCtD
Canagliflozin—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000245	0.0018	CcSEcCtD
Canagliflozin—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000244	0.00179	CcSEcCtD
Canagliflozin—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000243	0.00178	CcSEcCtD
Canagliflozin—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000243	0.00178	CcSEcCtD
Canagliflozin—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000243	0.00178	CcSEcCtD
Canagliflozin—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000243	0.00178	CcSEcCtD
Canagliflozin—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000242	0.00177	CcSEcCtD
Canagliflozin—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000241	0.00629	CbGeAlD
Canagliflozin—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000241	0.00177	CcSEcCtD
Canagliflozin—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00024	0.00176	CcSEcCtD
Canagliflozin—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000238	0.00175	CcSEcCtD
Canagliflozin—Rash—Didanosine—acquired immunodeficiency syndrome	0.000238	0.00174	CcSEcCtD
Canagliflozin—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000237	0.00174	CcSEcCtD
Canagliflozin—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000237	0.00174	CcSEcCtD
Canagliflozin—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000237	0.00174	CcSEcCtD
Canagliflozin—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000235	0.00173	CcSEcCtD
Canagliflozin—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000235	0.00173	CcSEcCtD
Canagliflozin—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000235	0.00172	CcSEcCtD
Canagliflozin—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000235	0.00172	CcSEcCtD
Canagliflozin—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000234	0.00172	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000233	0.00171	CcSEcCtD
Canagliflozin—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000232	0.00605	CbGeAlD
Canagliflozin—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000232	0.0017	CcSEcCtD
Canagliflozin—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000232	0.0017	CcSEcCtD
Canagliflozin—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000231	0.0017	CcSEcCtD
Canagliflozin—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000231	0.0017	CcSEcCtD
Canagliflozin—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.00168	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000229	0.00168	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000228	0.00168	CcSEcCtD
Canagliflozin—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000228	0.00167	CcSEcCtD
Canagliflozin—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000228	0.00167	CcSEcCtD
Canagliflozin—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000227	0.00167	CcSEcCtD
Canagliflozin—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000226	0.00166	CcSEcCtD
Canagliflozin—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000226	0.00166	CcSEcCtD
Canagliflozin—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000226	0.00166	CcSEcCtD
Canagliflozin—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000226	0.00165	CcSEcCtD
Canagliflozin—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000225	0.00165	CcSEcCtD
Canagliflozin—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000224	0.00164	CcSEcCtD
Canagliflozin—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000223	0.00583	CbGeAlD
Canagliflozin—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000223	0.00164	CcSEcCtD
Canagliflozin—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000223	0.00164	CcSEcCtD
Canagliflozin—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000221	0.00576	CbGeAlD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00022	0.00162	CcSEcCtD
Canagliflozin—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000219	0.0016	CcSEcCtD
Canagliflozin—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000217	0.0016	CcSEcCtD
Canagliflozin—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000217	0.00159	CcSEcCtD
Canagliflozin—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000217	0.00159	CcSEcCtD
Canagliflozin—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000217	0.00159	CcSEcCtD
Canagliflozin—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000216	0.00159	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000216	0.00159	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000216	0.00158	CcSEcCtD
Canagliflozin—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000215	0.00158	CcSEcCtD
Canagliflozin—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000215	0.00158	CcSEcCtD
Canagliflozin—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000215	0.00158	CcSEcCtD
Canagliflozin—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000214	0.00157	CcSEcCtD
Canagliflozin—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000214	0.00157	CcSEcCtD
Canagliflozin—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000213	0.00157	CcSEcCtD
Canagliflozin—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000213	0.00156	CcSEcCtD
Canagliflozin—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000211	0.00155	CcSEcCtD
Canagliflozin—ABCB1—blood—acquired immunodeficiency syndrome	0.00021	0.00548	CbGeAlD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.00021	0.00154	CcSEcCtD
Canagliflozin—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00021	0.00154	CcSEcCtD
Canagliflozin—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000209	0.00154	CcSEcCtD
Canagliflozin—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000209	0.00153	CcSEcCtD
Canagliflozin—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000209	0.00153	CcSEcCtD
Canagliflozin—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000207	0.00152	CcSEcCtD
Canagliflozin—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000207	0.00152	CcSEcCtD
Canagliflozin—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000207	0.00152	CcSEcCtD
Canagliflozin—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000207	0.00152	CcSEcCtD
Canagliflozin—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.00152	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000206	0.00151	CcSEcCtD
Canagliflozin—Rash—Stavudine—acquired immunodeficiency syndrome	0.000206	0.00151	CcSEcCtD
Canagliflozin—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000206	0.00151	CcSEcCtD
Canagliflozin—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000206	0.00151	CcSEcCtD
Canagliflozin—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000204	0.0015	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000204	0.0015	CcSEcCtD
Canagliflozin—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000204	0.0015	CcSEcCtD
Canagliflozin—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000204	0.00531	CbGeAlD
Canagliflozin—Rash—Abacavir—acquired immunodeficiency syndrome	0.000203	0.00149	CcSEcCtD
Canagliflozin—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000203	0.00149	CcSEcCtD
Canagliflozin—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000203	0.00528	CbGeAlD
Canagliflozin—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000202	0.00148	CcSEcCtD
Canagliflozin—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000201	0.00148	CcSEcCtD
Canagliflozin—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000201	0.00148	CcSEcCtD
Canagliflozin—Shock—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.00147	CcSEcCtD
Canagliflozin—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000199	0.00146	CcSEcCtD
Canagliflozin—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000199	0.00146	CcSEcCtD
Canagliflozin—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000198	0.00146	CcSEcCtD
Canagliflozin—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000197	0.00145	CcSEcCtD
Canagliflozin—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000197	0.00145	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000195	0.00143	CcSEcCtD
Canagliflozin—ABCB1—vagina—acquired immunodeficiency syndrome	0.000195	0.00508	CbGeAlD
Canagliflozin—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000195	0.00143	CcSEcCtD
Canagliflozin—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000195	0.00143	CcSEcCtD
Canagliflozin—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000194	0.00143	CcSEcCtD
Canagliflozin—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000191	0.0014	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000191	0.0014	CcSEcCtD
Canagliflozin—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000191	0.0014	CcSEcCtD
Canagliflozin—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.00019	0.00139	CcSEcCtD
Canagliflozin—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00019	0.00139	CcSEcCtD
Canagliflozin—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.00139	CcSEcCtD
Canagliflozin—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000189	0.00139	CcSEcCtD
Canagliflozin—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000189	0.00139	CcSEcCtD
Canagliflozin—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000188	0.00138	CcSEcCtD
Canagliflozin—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000187	0.00137	CcSEcCtD
Canagliflozin—ABCB1—lung—acquired immunodeficiency syndrome	0.000184	0.00481	CbGeAlD
Canagliflozin—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000184	0.00135	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000184	0.00135	CcSEcCtD
Canagliflozin—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000183	0.00135	CcSEcCtD
Canagliflozin—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000182	0.00134	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000181	0.00133	CcSEcCtD
Canagliflozin—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000179	0.00132	CcSEcCtD
Canagliflozin—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000179	0.00132	CcSEcCtD
Canagliflozin—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000179	0.00131	CcSEcCtD
Canagliflozin—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000177	0.0013	CcSEcCtD
Canagliflozin—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000176	0.00129	CcSEcCtD
Canagliflozin—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000176	0.00129	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000175	0.00129	CcSEcCtD
Canagliflozin—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000175	0.00128	CcSEcCtD
Canagliflozin—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000175	0.00128	CcSEcCtD
Canagliflozin—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000175	0.00128	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000174	0.00128	CcSEcCtD
Canagliflozin—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000174	0.00127	CcSEcCtD
Canagliflozin—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000172	0.00126	CcSEcCtD
Canagliflozin—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000171	0.00445	CbGeAlD
Canagliflozin—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000169	0.00124	CcSEcCtD
Canagliflozin—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000169	0.00124	CcSEcCtD
Canagliflozin—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000169	0.00124	CcSEcCtD
Canagliflozin—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.00123	CcSEcCtD
Canagliflozin—Rash—Indinavir—acquired immunodeficiency syndrome	0.000167	0.00122	CcSEcCtD
Canagliflozin—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000167	0.00122	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000166	0.00122	CcSEcCtD
Canagliflozin—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000165	0.00121	CcSEcCtD
Canagliflozin—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000164	0.00429	CbGeAlD
Canagliflozin—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000163	0.0012	CcSEcCtD
Canagliflozin—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000161	0.00118	CcSEcCtD
Canagliflozin—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.00118	CcSEcCtD
Canagliflozin—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000159	0.00116	CcSEcCtD
Canagliflozin—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000158	0.00116	CcSEcCtD
Canagliflozin—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000158	0.00116	CcSEcCtD
Canagliflozin—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000157	0.00115	CcSEcCtD
Canagliflozin—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000157	0.00115	CcSEcCtD
Canagliflozin—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000157	0.00115	CcSEcCtD
Canagliflozin—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000156	0.00115	CcSEcCtD
Canagliflozin—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000153	0.00112	CcSEcCtD
Canagliflozin—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000151	0.00111	CcSEcCtD
Canagliflozin—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000151	0.0011	CcSEcCtD
Canagliflozin—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000151	0.0011	CcSEcCtD
Canagliflozin—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00015	0.0011	CcSEcCtD
Canagliflozin—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000148	0.00109	CcSEcCtD
Canagliflozin—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000146	0.00107	CcSEcCtD
Canagliflozin—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000146	0.00107	CcSEcCtD
Canagliflozin—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000144	0.00105	CcSEcCtD
Canagliflozin—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000142	0.00104	CcSEcCtD
Canagliflozin—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.00103	CcSEcCtD
Canagliflozin—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000139	0.00102	CcSEcCtD
Canagliflozin—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000139	0.00102	CcSEcCtD
Canagliflozin—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000985	CcSEcCtD
Canagliflozin—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000134	0.000984	CcSEcCtD
Canagliflozin—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000134	0.000983	CcSEcCtD
Canagliflozin—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000131	0.000963	CcSEcCtD
Canagliflozin—ABCB1—brain—acquired immunodeficiency syndrome	0.000131	0.0034	CbGeAlD
Canagliflozin—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000128	0.000939	CcSEcCtD
Canagliflozin—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000128	0.000938	CcSEcCtD
Canagliflozin—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000126	0.000927	CcSEcCtD
Canagliflozin—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000126	0.00329	CbGeAlD
Canagliflozin—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000121	0.000885	CcSEcCtD
